No company will design a trial with double the patients they require to detect a positive result. The reason for such a big population was the the size of the improvement they were trying to detect was very small. That in itself should tell investors something about the likely efficacy of the treatment. The changes they have made may in fact have compromised the likelihood of success in order to reduce costs.
TEVA Update, page-17
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
0.010(0.66%) |
Mkt cap ! $1.741B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.54 | $1.48 | $5.605M | 3.713M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 55197 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.53 | 29782 | 3 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |